Investors interested in Medical - Instruments stocks are likely familiar with Integer (ITGR) and SONOVA HOLDING (SONVY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, ...

Shares of Integer (ITGR) have gained 3.2% over the past four weeks to close the last trading session at $116.55, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $150.38 indicates a potential upside of 29%.The mean estimate comprises eight short-term price targets with a standard deviation of $6.95. While the lowest estimate of $140 indicates a 20.1% increase from the current pri ...

PLANO, Texas, April 29, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced participation in the 2025 Bank of America Securities Health Care Conference, to be held May 13-15, 2025, in Las Vegas. Members of the Integer executive leadership team will participate in a fireside chat on Wednesday, May 14, at 10:00 a.m. PT. Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical dev ...

Integer Holdings Corporation (ITGR) delivered adjusted earnings per share (EPS) of $1.31 in the first quarter of 2025, which improved 14.9% year over year. The figure topped the Zacks Consensus Estimate by 3.2%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others.GAAP loss per share for the quarter was 66 cents, against EPS of 59 cents in the p ...

Integer (ITGR) Q1 2025 Earnings Call April 25, 2025 12:52 AM ET Company Participants Sanjiv Arora - SVP, Strategy, Business Development and IRJoseph Dziedzic - President & CEOPayman Khales - COODiron Smith - Executive VP & CFORichard Newitter - Managing DirectorNathan Treybeck - Equity Research Vice PresidentAndrew Cooper - VP - Equity ResearchJoanne Wuensch. - Managing DirectorSuraj Kalia - Managing Director Conference Call Participants Brett Fishbin - Vice President & Equity Research AnalystCraig Bijou - ...

Integer Holdings Corporation First Quarter 2025 Earnings Conference Call April 24, 2025 Integer Holdings Corporation First Quarter 2025 Earnings Conference Call 9 a.m. Eastern Time, April 24, 2025 Management Attendees: Diron Smith Executive Vice President, Chief Financial Officer Sanjiv Arora Senior Vice President, Strategy, Business Development & Investor Relations ITGR: 1Q25 Earnings Conference Call | April 24, 2025 | Page 2 Joe Dziedzic President, Chief Executive Officer Payman Khales President and CEO E ...

Integer (ITGR) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 3.15%. A quarter ago, it was expected that this medical device outsource manufacturer would post earnings of $1.46 per share when it actually produced earnings of $1.43, delivering a surprise of -2.05%. Over the last fou ...

EXHIBIT 99.1 Integer Holdings Corporation Reports First Quarter 2025 Results ~ Strong start to the year with 1Q25 financial results ~ ~ Reiterating 2025 sales and adjusted operating income outlook; raising adjusted EPS outlook ~ "Integer started the year off strong with first quarter 2025 sales growing at 7% year-over-year as we continue to execute our strategy by launching new products and adding capabilities in targeted growth markets. Integer also delivered 14% adjusted operating income growth," said Jos ...

Leadership Transition - Joseph Dziedzic will retire as President and CEO of Integer Holdings Corporation effective October 24, 2025, and will step down from the Board of Directors [1] - Payman Khales, currently the Chief Operating Officer, will assume the role of President and CEO and join the Board at that time [1] - To ensure a smooth transition, Dziedzic will serve as an advisor to the company until March 31, 2026 [1] Achievements and Strategy - Dziedzic's leadership over the past eight years has driven significant growth and value creation for Integer, focusing on high-growth markets and unmet patient needs [2] - Under Dziedzic, the company accelerated investments in differentiated technologies and implemented the Integer Production System to enhance manufacturing consistency [2] - Integer is currently achieving above-market organic sales growth with expanding margins, positioning the company for continued growth [2] Incoming CEO Profile - Payman Khales has been with Integer since 2018, initially as President of the Cardio & Vascular business, where he successfully doubled sales in seven years [3][5] - As COO, Khales has overseen both of Integer's business units and has been integral to the development and execution of the company's strategy [3][5] - Khales holds an Executive MBA from Indiana University's Kelley School of Business and a Bachelor of Science in Mechanical Engineering from École Polytechnique de Montréal [6] Company Overview - Integer Holdings Corporation is a leading medical device contract development and manufacturing organization, serving cardiac rhythm management, neuromodulation, and cardio and vascular markets [7] - The company is committed to enhancing patient lives through innovative, high-quality products and solutions, with brands including Greatbatch Medical and Lake Region Medical [7]

Core Insights - Integer (ITGR) is expected to report quarterly earnings of $1.27 per share, reflecting an 11.4% increase year-over-year, with revenues projected at $431.84 million, a 4.1% increase from the previous year [1] - Over the last 30 days, the consensus EPS estimate has been revised upward by 1.6%, indicating a positive reassessment by analysts [1][2] Revenue Estimates - Analysts predict 'Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation' to reach $162.26 million, showing a year-over-year increase of 3.8% [4] - 'Sales- Medical Sales- Advanced Surgical, Orthopedics & Portable Medical' is estimated at $22.58 million, reflecting a significant decline of 22.5% from the prior-year quarter [4] - 'Sales- Medical Sales- Cardio & Vascular' is expected to be $247.02 million, indicating an 11.4% increase compared to the same quarter last year [5] Market Performance - Integer shares have decreased by 1.5% over the past month, contrasting with the Zacks S&P 500 composite's decline of 8.9% [6] - The company holds a Zacks Rank of 3 (Hold), suggesting it is likely to perform in line with the overall market in the near term [6]